Loading
Aptevo Therapeutics
Aptevo Therapeutics is a Seattle company that builds antibody-like proteins which point the immune system at cancer. Its lead medicine, mipletamig, links T cells to leukaemia cells and is being tested in newly diagnosed acute myeloid leukaemia.
Also called: Aptevo Therapeutics Inc.
Overview
Aptevo Therapeutics Inc., of Seattle, describes itself in its August 2026 registration statement as a clinical-stage company developing immunotherapies for cancer on two platforms it wholly owns, ADAPTIR and ADAPTIR-FLEX, with two clinical and six preclinical candidates. Mipletamig is a CD123 x CD3 T cell engager with a CRIS-7 CD3-binding domain, evaluated in RAINIER, a phase 1b/2 programme started in August 2024 in frontline acute myeloid leukaemia with venetoclax and azacitidine in patients unfit for intensive chemotherapy. ALG.APV-527 targets the co-stimulatory receptor 4-1BB and the tumour antigen 5T4 and is being evaluated in several solid tumour types.
Headquarters
Seattle, WA, US
Scorecard
All companies#398of 1706 companies, score 11
- phase 1/2 +1
- targets +6
- modalities +4
0 approved, 0 in phase 3, 1 earlier, 3 targets, 0 registry studies. Formula on the scorecards page.
Type
Biotech · APVO
Stage
Public
Website
Products
2Phase 1Bispecific T cell engager
Mipletamig is a two-armed protein from Aptevo Therapeutics that holds a leukaemia cell and a T cell together so the T cell kills it. It is in an early trial with standard drugs in newly diagnosed acute myeloid leukaemia.
Bispecific antibody (4-1BB x 5T4)
ALG.APV-527 is an antibody-like protein from Aptevo Therapeutics that switches on immune cells only where it finds a marker on tumour cells. It is being tested in several kinds of solid tumour.
Notes
- Read on 4 November 2026 in the S-1 filed with the SEC on 21 August 2026, which incorporates the annual report by reference. No 5T4 target record exists in OnCo. Trial registry numbers are not given in the filing.
Connected
8Similar pages
- CompanyAdaptin Bio
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific).
- CompanyJanux Therapeutics
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific).
- CompanyXencor
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific).
- CompanyBeijing Immunoah Pharma Tech
- PersonAjai Chari
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific).
- CompanyIGM Biosciences
- CompanyDuboce Biopharmaceuticals
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific).
- TreatmentM701
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific).
fronts
technologies
targets
drugs
Bispecific antibody (4-1BB x 5T4)
Phase 1Bispecific T cell engager
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
aptevotherapeutics.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/